Lake Forest, CA, May 7, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal husbandry and reproductive medicine, announced today that its Chief Executive Officer, Jerrell Shelton, is scheduled to present at the 2015 Marcum MicroCap Conference at the Grand Hyatt in New York City on Thursday, May 28, 2015 at 9:30 a.m. EDT.
During the presentation, Mr. Shelton will discuss the Company’s growth strategy and expansion of its solutions and service offerings to further accelerate revenue growth. As a result of the expanding life sciences market, Cryoport is experiencing significant interest and demand for its innovative, validated cryogenic logistics solutions. Cryoport management understands the challenges life sciences companies face when moving temperature-sensitive biologics and the Company’s solutions eliminate logistical risks with reliable and innovative cryogenic logistics solutions. Cryoport’s validated solutions assure both its clients and their end-users that the integrity of shipments are maintained with clear visibility throughout the entire documented logistics process. All ‘chain-of-custody’ and, if requested by the client, ‘chain-of-condition’ data is maintained in Cryoport’s cloud-based Logistics Management Platform, the CryoportalTM, giving its clients secure and immediate access to their data for regulatory and quality assurance purposes.
Investors interested in the life sciences and who wish to meet with Cryoport’s management team in one-on-one meetings during the conference should contact KCSA Strategic Communications at firstname.lastname@example.org or call 212.682.6300.
For information and registration to the Marcum MicroCap Conference, please visit the conference website: http://www.marcumllp.com/Microcap.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press releaseInvestor Contacts:
Todd Fromer / Garth Russell
email@example.com / firstname.lastname@example.org
P: 1 212-682-6300